Literature DB >> 15999993

Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.

Steven Harper1, Salvatore Avolio, Barbara Pacini, Marcello Di Filippo, Sergio Altamura, Licia Tomei, Giacomo Paonessa, Stefania Di Marco, Andrea Carfi, Claudio Giuliano, Julio Padron, Fabio Bonelli, Giovanni Migliaccio, Raffaele De Francesco, Ralph Laufer, Michael Rowley, Frank Narjes.   

Abstract

Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. Compounds that block replication of subgenomic HCV RNA in liver cells are of interest because of their demonstrated antiviral effect in the clinic. In followup to our recent report that indole-N-acetamides (e.g., 1) are potent allosteric inhibitors of the HCV NS5B polymerase enzyme, we describe here their optimization as cell-based inhibitors. The crystal structure of 1 bound to NS5B was a guide in the design of a two-dimensional compound array that highlighted that formally zwitterionic inhibitors have strong intracellular potency and that pregnane X receptor (PXR) activation (an undesired off-target activity) is linked to a structural feature of the inhibitor. Optimized analogues devoid of PXR activation (e.g., 55, EC(50) = 127 nM) retain strong cell-based efficacy under high serum conditions and show acceptable pharmacokinetics parameters in rat and dog.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999993     DOI: 10.1021/jm050056+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Structure-function relationships among RNA-dependent RNA polymerases.

Authors:  Kenneth K S Ng; Jamie J Arnold; Craig E Cameron
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

3.  A small molecule inhibits HCV replication and alters NS4B's subcellular distribution.

Authors:  Paul D Bryson; Nam-Joon Cho; Shirit Einav; Choongho Lee; Vincent Tai; Jill Bechtel; Mohan Sivaraja; Chris Roberts; Uli Schmitz; Jeffrey S Glenn
Journal:  Antiviral Res       Date:  2010-04-02       Impact factor: 5.970

4.  Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.

Authors:  Cliff C Cheng; Xiaohua Huang; Gerald W Shipps; Yu-Sen Wang; Daniel F Wyss; Kyle A Soucy; Chuan-Kui Jiang; Sony Agrawal; Eric Ferrari; Zhiqing He; H-C Huang
Journal:  ACS Med Chem Lett       Date:  2010-08-17       Impact factor: 4.345

Review 5.  Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine.

Authors:  Zdeněk Dvořák; Harry Sokol; Sridhar Mani
Journal:  Trends Pharmacol Sci       Date:  2020-10-20       Impact factor: 14.819

Review 6.  Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.

Authors:  Michael Sinz; Gillian Wallace; Jasminder Sahi
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

7.  In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.

Authors:  Min Jiang; Nagraj Mani; Chao Lin; Andrzej Ardzinski; Michelle Nelson; Dugan Reagan; Doug Bartels; Yi Zhou; Olivier Nicolas; B Govinda Rao; Ute Müh; Brian Hanzelka; Ann Tigges; Rene Rijnbrand; Tara L Kieffer
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

8.  Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.

Authors:  Ravindra K Rawal; S B Katti; Neerja Kaushik-Basu; Payal Arora; Zhenhua Pan
Journal:  Bioorg Med Chem Lett       Date:  2008-10-08       Impact factor: 2.823

9.  Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.

Authors:  Samir Ali; Vincent Leveque; Sophie Le Pogam; Han Ma; Friederike Philipp; Nicole Inocencio; Mark Smith; Andre Alker; Hyunsoon Kang; Isabel Najera; Klaus Klumpp; Julian Symons; Nick Cammack; Wen-Rong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

10.  Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors.

Authors:  Beilei Lei; Juan Du; Shuyan Li; Huanxiang Liu; Yueying Ren; Xiaojun Yao
Journal:  J Comput Aided Mol Des       Date:  2008-08-21       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.